ArticleJournal of enzyme inhibition and medicinal chemistry2023
Unveiling the mechanism of action of acylated temporin L analogues against multidrug-resistant
Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Chemical Optimization of Temporin A-L Peptides: From Native Isoforms to Enhanced Antimicrobial Analogs.ChemMedChem · 2026Review
- Antimicrobial Activity of Bioactive Peptides on Resistant Enterobacteriaceae and the Viability ofVeterinary sciences · 2026Article
- Probing Guanidino Pendant or Bridged Groups in Cyclic Antimicrobial Peptides Derived from Temporin L: A Strategy to Improve Efficacy against Gram-Negative Bacteria.Journal of medicinal chemistry · 2025Article
- A Serum-Stable Antimicrobial Peptide-Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Antimicrobial Peptides: Current Status, Mechanisms of Action, and Strategies to Overcome Therapeutic Limitations.Microorganisms · 2025Review
- Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle.ACS applied materials & interfaces · 2025Article
- Temporizin-1 Meets the Membranes: Probing Membrane Inser-Tion and Disruption Mechanisms.Antibiotics (Basel, Switzerland) · 2025Article
- Boosting AMPs' Power: From Structural Engineering to Nanotechnology-Based Delivery.Molecules (Basel, Switzerland) · 2025Review
- Engineering Multifunctional Peptide-Decorated Nanofibers for Targeted Delivery of Temozolomide across the Blood-Brain Barrier.Molecular pharmaceutics · 2025Article
- Strategic Single-Residue Substitution in the Antimicrobial Peptide Esc(1-21) Confers Activity againstACS infectious diseases · 2024Article
- Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.International journal of nanomedicine · 2024Article
- Glycosylation and Lipidation Strategies: Approaches for Improving Antimicrobial Peptide Efficacy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Myxinidin-Derived Peptide against Biofilms Caused by Cystic Fibrosis Emerging Pathogens.International journal of molecular sciences · 2023Article
- An Overview of Supramolecular Platforms Boosting Drug Delivery.Bioinorganic chemistry and applications · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing resistance of fungi to conventional antifungal drugs has prompted worldwide the search for new compounds. In this work, we investigated the antifungal properties of acylated Temporin L derivatives,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.